Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma
High-dose chemotherapy (HD-CT) in combination with autologous stem cell transplantation (auto-SCT) has long become the gold standard treatment for chemosensitive recurrences and refractory diffuse large B-cell lymphoma (DLBCL). By taking into account the low efficiency of rescue therapy (postrecurre...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2013-07-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31340 |
id |
doaj-2b7b41315bec4e7ba958695bf36608ce |
---|---|
record_format |
Article |
spelling |
doaj-2b7b41315bec4e7ba958695bf36608ce2020-11-25T03:06:08Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422013-07-01857909728356Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphomaO A GavrilinaN G GabeevaA K MorozovaA A SidorovaE E ZvonkovHigh-dose chemotherapy (HD-CT) in combination with autologous stem cell transplantation (auto-SCT) has long become the gold standard treatment for chemosensitive recurrences and refractory diffuse large B-cell lymphoma (DLBCL). By taking into account the low efficiency of rescue therapy (postrecurrence five-year survival rate is not more than 10-20%), it is clear that the results of treatment should be improved in the induction of the first remission. The study performed in the rituximab time showed the higher efficiency of first-line therapy using auto-SCT. Therapeutic effectiveness was also noted to depend on the intensity of pretransplantation regimens. Indications for HD-CT with auto-SCT must be substantiated because of the higher toxicity together with therapy intensification. Conventional clinical criteria for this are insufficient. Thus, it is necessary to search for new molecular genetic prognostic factors that will be able to portray tumor biology.https://ter-arkhiv.ru/0040-3660/article/view/31340diffuse large b-cell lymphomahigh-dose chemotherapyautologous stem cell transplantationpoor predictors |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
O A Gavrilina N G Gabeeva A K Morozova A A Sidorova E E Zvonkov |
spellingShingle |
O A Gavrilina N G Gabeeva A K Morozova A A Sidorova E E Zvonkov Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma Терапевтический архив diffuse large b-cell lymphoma high-dose chemotherapy autologous stem cell transplantation poor predictors |
author_facet |
O A Gavrilina N G Gabeeva A K Morozova A A Sidorova E E Zvonkov |
author_sort |
O A Gavrilina |
title |
Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma |
title_short |
Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma |
title_full |
Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma |
title_fullStr |
Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma |
title_full_unstemmed |
Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma |
title_sort |
role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large b-cell lymphoma |
publisher |
"Consilium Medicum" Publishing house |
series |
Терапевтический архив |
issn |
0040-3660 2309-5342 |
publishDate |
2013-07-01 |
description |
High-dose chemotherapy (HD-CT) in combination with autologous stem cell transplantation (auto-SCT) has long become the gold standard treatment for chemosensitive recurrences and refractory diffuse large B-cell lymphoma (DLBCL). By taking into account the low efficiency of rescue therapy (postrecurrence five-year survival rate is not more than 10-20%), it is clear that the results of treatment should be improved in the induction of the first remission. The study performed in the rituximab time showed the higher efficiency of first-line therapy using auto-SCT. Therapeutic effectiveness was also noted to depend on the intensity of pretransplantation regimens. Indications for HD-CT with auto-SCT must be substantiated because of the higher toxicity together with therapy intensification. Conventional clinical criteria for this are insufficient. Thus, it is necessary to search for new molecular genetic prognostic factors that will be able to portray tumor biology. |
topic |
diffuse large b-cell lymphoma high-dose chemotherapy autologous stem cell transplantation poor predictors |
url |
https://ter-arkhiv.ru/0040-3660/article/view/31340 |
work_keys_str_mv |
AT oagavrilina roleofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithdiffuselargebcelllymphoma AT nggabeeva roleofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithdiffuselargebcelllymphoma AT akmorozova roleofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithdiffuselargebcelllymphoma AT aasidorova roleofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithdiffuselargebcelllymphoma AT eezvonkov roleofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithdiffuselargebcelllymphoma |
_version_ |
1724675089581998080 |